Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers - Seite 2
The efficacy results including ORR and six-month PFS rates are summarized in the table below:
|
PD-L1-high* |
(TAP ≥5%)
N=15
n (%)
PD-L1-low*
(TAP <5%)
N=24
n (%)
Overall
N=41
n (%)
ORR (95% CI)
80%
(52,96)
46%
(26,67)
59%
(42,74)
Confirmed ORR (95% CI)
73%
(45,92)
46%
(26,67)
56%
(40,72)
6-month PFS Rate (95% CI)
93%
(81,100)
68%
(48,88)
77%
(64,90)
*Tumor samples from 2 patients were not available for central PD-L1 testing
CI: confidence interval
The domvanalimab-containing regimen was well tolerated, with a similar safety profile to what has been reported for anti-PD-1 plus chemotherapy in this setting. The most common adverse events (AEs) were neutropenia (59%), nausea (54%), anemia (27%) and fatigue (27%). Infusion-related reactions were observed in 20% and the majority (17%) were related to chemotherapy. No patients experienced serious immune-mediated AEs, and there were no treatment-emergent adverse events (TEAEs) resulting in death.
These data add to the growing body of evidence that domvanalimab, an Fc-silent anti-TIGIT antibody, has a differentiated safety and tolerability profile relative to published data from studies with Fc-enabled anti-TIGIT antibodies.
Lesen Sie auch
The preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study support the ongoing Phase 3 study, STAR-221, in unresectable or metastatic upper GI cancers. The companies have three additional ongoing Phase 3 registrational studies of domvanalimab-containing regimens in lung cancer, including STAR-121, ARC-10 and PACIFIC-8.